Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain
نویسندگان
چکیده
منابع مشابه
Budget Impact Analysis of Apremilast In Patients With Psoriasis In The Italian Setting.
BACKGROUND • Plaque psoriasis is a lifelong chronic, inflammatory skin condition that affects approximately 2.9% of the adult population in Italy.1 • Apremilast is an orally administered, small-molecule phosphodiesterase 4 inhibitor. It has a novel mechanism of action, targeting multiple steps in the pathogenesis of psoriasis. The marketing authorisation from the European Medicines Agency for t...
متن کاملCost-Effectiveness of Apremilast In Psoriatic Arthritis In Scotland.
events were considered, reflecting the year 2015. All outcomes were discounted at 3.5% annually. Results: Regarding the AS subpopulation, the total treatment cost for IFX, ADA, CZP, ETA, GOL and CC was: € 67,736, € 38,914, € 38,721, € 38,290, € 35,338 and € 4,110; and the quality-adjusted life years (QALYs) were: 10.031, 9.882, 9.949, 9.933, 9.903 and 9.360, respectively. CZP dominated ADA and ...
متن کاملClinical potential of apremilast in the treatment of psoriatic arthritis
Psoriatic arthritis (PsA) is a frequent chronic inflammatory disease characterized by joint and skin involvement, and by typical extra-articular manifestations. Although the pathogenesis of PsA is still under investigation, the available evidence suggests the importance of the patient's genetic background, microbial or environmental triggers, and an imbalance in the adaptive and acquired immune...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2015
ISSN: 1098-3015
DOI: 10.1016/j.jval.2015.09.2313